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Abstract
Background: Due to the increasing number of long-term (≥5 years post diagnosis) colorectal cancer survivors,
long-term quality of life of these patients is highly relevant. Several studies have reported a positive association
between physical activity and quality of life in colorectal cancer survivors, however, so far no systematic review has
been published which focuses on long-term colorectal cancer survivors.
Material and methods: A systematic review was conducted using the databases PubMed, Web of Science,
PsychINFO, and CINAHL. Studies which investigated associations between physical activity and quality of life in
long-term colorectal cancer survivors were included.
Results and conclusion: Ten articles based on seven studies were identified. Long-term colorectal cancer survivors
who were physically active reported better quality of life than long-term survivors who were not physically active.
Both, moderate to vigorous physical activity and lower levels like light physical activity were associated with higher
quality of life. Most studies assessed the association between physical activity and quality of life cross-sectionally
but one prospective study which measured physical activity and quality of life at three different points in time also
found associations between physical activity and quality of life. The association between physical activity and
quality of life seemed to be stronger among women than among men. The findings of this systematic review
support an association between physical activity and quality of life in long-term colorectal cancer survivors.
However, the evidence is limited as most studies were based on cross-sectional and observational design.
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Background
In 2012, there were almost 1.4 million incident cases
and roughly 700,000 deaths due to colorectal cancer
(CRC) worldwide [1]. Colorectal cancer is the second
most common cancer and the second leading cause of
cancer-related deaths in Europe [2].
There is strong evidence that physical activity (PA), in
particular leisure-time PA, is associated with better overall
[3–6] as well as CRC-specific [4, 5] survival in CRC pa-
tients. According to a recent meta-analysis based on 7422
CRC patients, PA after diagnosis was associated with a
39% lower risk of CRC-specific mortality [5]. Moreover,
evidence from several studies [7–9] further suggests that
PA might have a positive effect on quality of life (QOL) in
CRC survivors. Studies have shown that patients who
were more physically active tended to report better QOL,
better functioning, less pain, insomnia, and fatigue [8, 9].
However, a recent review article by Lynch et al. [10] re-
ported inconsistent results of studies which investigated
the association between PA and QOL in short-term and
long-term (≥5 years post-diagnosis) CRC survivors. Al-
though observational studies unanimously observed asso-
ciations between PA and QOL, the evidence is much
weaker from intervention studies. No systematic review to
date has focused specifically on associations between PA
and QOL in long-term CRC survivors.
Due to recent improvements in early detection and treat-
ment, the 5 year survival-rate of CRC has increased up to
66% [11, 12]. Thus, the QOL of long-term CRC survivors is
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a highly relevant issue. Although a number of studies [13–
15] found that the overall QOL of CRC survivors was com-
parable to the general population, they also reported that
CRC survivors experience detriments in symptom-related
QOL, even years after diagnosis. Studies [13, 16] further
suggest that detriments in QOL might be largest among
younger CRC survivors compared to cancer controls. Also,
the QOL of CRC survivors has been shown to change
throughout the years after diagnosis. Jansen et al. found that
facets of QOL, such as physical functioning and pain wors-
ened over a 10-year follow-up period [16]. Moreover, it has
been reported that CRC survivors experience different psy-
chosocial and physical symptoms at various points in time
after diagnosis; for example shortly after treatment survivors
reported more frequently symptoms such as neuropathy
and sleep difficulty [17] whereas long-term CRC survivors
reported to have symptoms such as bowel problems, stress
related to cancer, and depression [18]. Due to these differ-
ences in psychosocial and physical symptoms between
short-term and long-term survivors, we hypothesize that
the overall effect of PA on QOL might vary.
As PA may represent a promising intervention to im-
prove QOL and alleviate the burden of living with can-
cer and since there has not been much research in this
field, this review summarizes the current available evi-
dence investigating the association between PA and
QOL in long-term CRC survivors.
Materials and methods
The literature search was carried out in August 2016 and
was repeated in January 2017 to guarantee inclusion of all
relevant publications. The databases PubMed, Web of Sci-
ence, PsychINFO and CINAHL were searched for relevant
articles. The exact combinations of search terms are listed
in the Additional file 1: Table S1. Cross-referencing was
performed to identify additional articles which were not
identified by the database search.
Inclusion criteria
To be included in the review, studies had to assess QOL
in CRC patients 5 and more years post-diagnosis and PA
within the time span of diagnosis to QOL assessment.
Results of studies which investigated short-term as well
as long-term survivors were also eligible if specific re-
sults for long-term survivors were provided. Studies
comprising survivors with a mean of ≥5 years since diag-
nosis were also included. We did not include studies
examining PA/QOL among CRC survivors regardless of
time since diagnosis, since testing for a moderating ef-
fect of time was not our major interest. All types of CRC
and all kinds of PA were eligible. However, QOL had to
be assessed by more than one scale as it is a multidi-
mensional concept. When studies investigated several
cancer types, only the specific results for CRC survivors
were included. Furthermore, PA had to be the independ-
ent variable and QOL the outcome. All types of quanti-
tative original studies, published in English or German,
were included. Conference abstracts, study protocols,
editorials, commentaries, qualitative studies, theses, re-
views, and meta-analyses were not considered. There
was no restriction regarding the publication date.
Data extraction
Titles and abstracts of all identified articles were screened
by the first reviewer (RE). Subsequently the full texts of
the selected articles were checked for eligibility. The study
characteristics of the eligible studies (e.g. first author, year,
journal, sample size, country, sex, age, tumor site, cancer
stage, cancer treatment, sampling, study design, comor-
bidities, inclusion and exclusion criteria, baseline response
rate, timing/type of PA assessment, timing/type of QOL
assessment, confounders/adjustment, statistical methods,
results) were independently extracted by two reviewers
(RE and KX). Discrepancies were discussed and if they
could not be solved, a third reviewer (VA) was involved.
Statistical significance and clinical relevance
All statistically significant results mentioned in this re-
view refer to a p-value <0.05. If studies reported clinical
relevance using either the European Organization for
Research and Treatment of Cancer QLQ-C30 question-
naire (EORTC QLQ-C30) or the Short Form Health Sur-
vey (SF-36), the reported clinical relevance was adopted.
For those studies using the EORTC QLQ-C30 and not
reporting clinical relevance, we determined clinical rele-
vance by using a medium clinical relevance, which is de-
fined by Osoba et al. [19] as a mean difference of ≥10
score points.
Combining the results of different QOL instruments
As the included studies used various QOL instruments
with different notation for the embedded scales, results
pertaining different QOL scales of different question-
naires were combined as shown in Table 1.
Two reviewers (RE and KX) checked the methodo-
logical quality of each included article using items
adapted from the checklist of Mols et al. [20], with a
more detailed emphasis on contents that are important
to the specific study question of this review (Table 2).
The following quality criteria were considered:
1) Information bias:
a) Adequate assessment of exposure (i.e. valid PA
instrument, assessment of all PA aspects,
objective measure rather than self-report)
b) Adequate assessment of outcome (i.e. valid
QOL instrument, assessment of all relevant
QOL aspects)
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c) Adequate description of data (socio-
demographic and medical data is described
e.g. age, tumor stage at diagnosis etc.; the
process of data collection is described e.g.
interview or self-report)
2) Selection bias:
a) Inclusion and/or exclusion criteria are
formulated
b) Healthy (survivor) participation bias (i.e.
information about non-participants at base-
line, information about drop-outs at follow-
up, attrition bias)
3) Study design:
a) Description of timing of PA/QOL
assessment
b) Adequate information regarding time since
diagnosis
c) Adequate sample size and power
d) Prospective study design rather than cross-
sectional
4) Correction of outcome measures for confounding
(e.g. age, sex, comorbidities)
This systematic review was guided by the criteria, set
out by the PRISMA guidelines [21].
Results
Literature search
The search identified 988 articles (Fig. 1). After remov-
ing the duplicates, 740 publications remained. After
checking titles and abstracts for eligibility, 80 relevant
articles were identified. Thirty articles were excluded be-
cause they were not original articles, and 32 were ex-
cluded because they did not include long-term CRC
survivors. Two studies [22, 23] assessed QOL on only
one scale and were therefore excluded. One study [24]
did not report any results regarding the association of
PA and QOL. One study [25] did not report separate re-
sults for CRC survivors and four studies [26–29] were
excluded for several other reasons. In the end, ten arti-
cles based on seven studies were included in this system-
atic review. Two articles of Blanchard et al. [30, 31] were
Table 1 Combining the results of different QOL instruments
Questionnaire Scale
Global QOL EORTC QLQ-
C30 [45]
Overall QOL/ global health
SF-36 [46] General health and global health
composite score
EQ-5D [47] Overall health related quality of life
(HRQOL)
Physical functioning EORTC QLQ-
C30
Physical functioning
SF-36 Physical functioning and physical
health composite score
FACT-C [48] Physical well-being
PROMIS [49] Physical HRQOL
Role functioning EORTC QLQ-
C30
Role functioning
SF-36 Role physical
FACT-C Functional well-being
Social functioning EORTC QLQ-
C30
Social functioning
SF-36 Social functioning
FACT-C Social well-being
Emotional
functioning
EORTC QLQ-
C30
Emotional functioning
SF-36 Mental health
FACT-C Emotional well-being
Table 2 Quality assessment of included studies
First author year (ref.)
country
Potential Limitations
Blanchard 2004 [35]
USA
- No validated PA questionnaire used
- Possible response bias due to
self-reported PA
- Sample size < 100
- Cross-sectional study design
Blanchard 2008 [30]a
USA
- Possible response bias due to self-reported PA
- Only assessment of leisure-time PA
- Cross-sectional study design
Blanchard 2010 [31]a
USA
- Possible response bias due to self-reported PA
- Only assessment of leisure-time PA
- Cross-sectional study design
Chambers 2012 [38]
Australia
- Possible response bias due to self-reported PA
- Only assessment of leisure-time PA
Husson 2015 [34]b
The Netherlands
- Possible response bias due to self-reported PA
Mols 2015 [9]b
The Netherlands
- Possible response bias due to self-reported PA
- Cross-sectional study design
Rodriguez 2015 [36]
USA
- Possible response bias due to self-reported PA
- Cross-sectional study design
Thraen-Borowski 2013 [37]
USA
- Possible response bias due to self-reported PA
- Only assessment of leisure-time PA
- Cross-sectional study design
Van Roekel 2015 [32]c
The Netherlands
- Possible response bias due to self-reported PA
- Cross-sectional study design
Van Roekel 2016 [33]c
The Netherlands
- Cross-sectional study design
aArticles based on same study population: American Cancer Society’s Study of
Cancer Survivors-II (SCS-II); bArticles based on same study population: All
patients diagnosed between 2000 and 2009 and registered in the Patient
Reported Outcomes Following Initial treatment and Long term Evaluation of
Survivorship (PROFILES registry); cArticles based on same study population:
Energy for life after ColoRectal cancer (EnCoRe)
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based on the same study population (American Cancer
Society’s Study of Cancer Survivors-II, SCS-II). Also the
data for the two articles of van Roekel et al. [32, 33]
were taken from an identical study population (Energy
for life after ColoRectal cancer, EnCoRe). Further, all
CRC patients diagnosed between 2000 and 2009 as reg-
istered in the PROFILES cancer registry were selected
for the articles of Mols et al. [9] and Husson et al. [34].
In case of multiple articles per study, each study only
counted once but results from all articles are shown in
the tables.
Study characteristics
Participants’ characteristics
Four studies were conducted in the US [30, 31, 35–37],
two [9, 32–34] in the Netherlands and one in Australia
[38] (Table 3). Sample sizes ranged from 86 [35] to
1918 [30]. All of the included studies investigated fe-
male and male survivors, but most reported a slightly
higher proportion of males. The mean age at time of
QOL assessment ranged from 68.4 [34] to 81.5 [37]
years. Two studies were restricted to long-term survi-
vors only [36, 37]. All the other studies [9, 30–35, 38]
did not provide specific results for long-term CRC sur-
vivors, but comprised survivors with a mean of ≥5 years
since diagnosis at the time of QOL assessment. Four
studies [30–35] included CRC survivors from 2 years
post-diagnosis, one prospective study [38] included par-
ticipants from five months post-diagnosis, but the re-
sults for the association between PA and QOL was
based on PA and QOL data collected 5 years
post-diagnosis. Mols et al. [9] included survivors from
1 year up to 11 years post-diagnosis.
The majority of the studies [9, 30, 32, 33, 35] pro-
vided information regarding treatment, such as propor-
tions of patients undergoing surgery, chemotherapy and
radiation. Three studies included patients with metasta-
ses [9, 30, 31, 34, 35], three studies [32, 33, 36, 38] ex-
cluded patients with metastases and one study [37] did
not report cancer stage. Four studies [35–38] solely
Fig. 1 Literature search process. QOL: quality of life; PA: physical activity; CRC: colorectal cancer
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Table 3 Study characteristics
First author
year (ref.)
country
Study design Sample
size
Age at survey Time since
diagnosisa
Cancer
treatment
Cancer
stage
PA
instrument
QOL
instrument
Meeting ACS
PA guideline
Blanchard
2004 [35]
USA
Cross-sectional,
population-based
86 Mean(SD)
69.22(12.5)
≥2 years 33.7%
≥5 years 30.2%
≥10 years
36.0%
Surgery
Radiation
Chemotherapy
I-IV Adherence
to ACS PA
guideline
SF-36 69.8%
Blanchard
2008 [30]b
USA
Cross-sectional,
population-based
1918 Mean(SD)
70.2(11.0)
≥2 years 33.4%
≥5 years 35.3%
≥10 years
31.3%
Surgery
Radiation
Chemotherapy
Hormone
therapy
Immuno
therapy
BMT
I-IV GLTEQ SF-36 35%
Blanchard
2010 [31]b
USA
Cross-sectional,
population-based
668 Mean(SD)
70.2(11.1)
≥2 years 26.8%
≥5 years 40.5%
≥10 years
32.0%
In treatment
(not further
specified)
I-IV GLTEQ SF-36 HW 20.0%
OW 30.0%
OB 24.4%
Chambers
2012 [38]
Australia
Cross-sectional &
longitudinal,
population-based
632 Mean
69.02
≥5 years
Mean(SD)
5(6.1)
Surgery
Chemotherapy
I-III AAS FACT-C
SWLS
–
Husson
2015 [34]c
The
Netherlands
Cross-sectional &
longitudinal,
population-based
1739 Mean(SD)
68.4(9.4)
≥2 years
Mean(SD)
5.1(2.8)
Radiation
Chemotherapy
I-IV EPIC EORTC
QLQ-C30
82%
Mols 2015
[9]c
The
Netherlands
Cross-sectional,
population-based
1648 Mean(SD)
Chemotherapy:
66.7(9.8)
No
chemotherapy:
70.6(9.0)
1–11 years
Mean(SD)
Chemotherapy:
5.6(2.8)
No
chemotherapy:
6.1(2.8)
Surgery
Radiation
I-IV EPIC EORTC
QLQ-C30
CIPN20
Chemotherapy:
93%
No
Chemotherapy:
89%
Rodriguez
2015 [36]
USA
Cross-sectional,
population-based
593 Mean 73.8 Only ≥5 years
Mean
6.2
Number of
treatments
I-III GLTEQ PROMIS
EQ-5D
–
Thraen-
Borowski
2013 [37]
USA
Cross-sectional,
population-based
832 Mean(SD)
81.5(5.8)
Only ≥5 years
Mean(SD)
8.2(1.7)
– – CHAMPS SF-36 52%
Van Roekel
2015 [32]d
The
Netherlands
Cross-sectional,
mono-centric
151 Mean(SD)
69.8(8.7)
2–10 years
Mean(SD)
5.7(1.8)
Surgery
Radiation
Chemotherapy
I-III SQUASH EORTC
QLQ-C30
WHODAS
II
CIS
HADS
71%
Van Roekel
2016 [33]d
The
Netherlands
Cross-sectional,
mono-centric
145 Mean(SD)
70.0(8.7)
2–10 years
Mean(SD)
5.7(1.9)
Surgery
Radiation
Chemotherapy
I-III MMOXX1 EORTC
QLQ-C30
WHODAS
II
CIS
HADS
–
Ref. Reference, PA physical activity, QOL quality of life, ACS PA guideline American Cancer Society physical activity recommendations of at least 150 min of MVPA
per week, SF-36 The Short Form Health Survey, BMT Bone marrow transplantation, GLTEQ Godin Leisure-Time Exercise Questionnaire, HW healty weight, OW over
weight, OB obese, AAS The Active Australian Survey, FACT-C Functional Assessment of Cancer Therapy-General (FACT-G) plus CRC-specific measurements, SWLS
Satisfaction With Life Scale, EPIC European Prospective Investigation into Cancer Physical Activity Questionnaire, EORTC QLQ-C30 European Organization for
Research and Treatment of Cancer QLQ-C30 questionnaire, CIPN20 European Organization for Research and Treatment of Cancer QLQ-CIPN20 Chemotherapy-
induced peripheral neuropathy questionnaire PROMIS Patient-Reported Outcomes Measurement Information System, EQ-5D EuroQol Five-Dimension
Questionnaire, CHAMPS The Community Healthy Activities Model Program for Seniors, SQUASH The Short Questionnaire to Assess Health-enhancing physical
activity, WHODAS World Health Organization Disability Assessment Schedule, CIS Checklist Individual Strength, HADS Hospital Anxiety and Depression Scale,
MMOXX1 Triaxial MOX activity monitor, aTime since diagnosis at time point of QOL assessment; bArticles based on same study population: American Cancer
Society’s Study of Cancer Survivors-II (SCS-II); cArticles based on same study population: All patients diagnosed between 2000 and 2009 and registered in the
Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES registry); dArticles based on same study population:
Energy for life after ColoRectal cancer (EnCoRe)
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included survivors with a primary diagnosis of CRC,
the other studies did not give information about inclu-
sion of survivors with other cancer diagnoses. Four arti-
cles [31–33, 36] reported the inclusion of patients with
cancer recurrence.
Regarding cancer site, all studies included patients
with colon as well as rectal cancers. Five studies [9, 32–
34, 36–38] included solely patients with CRC, whilst two
studies [30, 31, 35] also included patients with other
cancer types. However, the results regarding the associ-
ation between PA and QOL as well as all figures shown
in Table 3 are CRC-specific, only response rates are re-
ported for all cancer types together [30, 31, 35].
Study design
All included studies were observational in design. Recruit-
ment methods varied across studies, six [9, 30, 31, 34–38]
used population-based recruitment, and one [32, 33]
was completed in a single institution. Two of the articles
[34, 38] were prospective, longitudinal designs assessing
PA and/or QOL at multiple points in time, while the
remaining eight were cross-sectional [9, 30–33, 35–37].
Response rate and follow-up rate
The response rates in the aforementioned cross-sectional
studies ranged from 33% [30] (not CRC-specific) to
83% [9]. Husson et al. [34] reported a participation of
73% at baseline, 83% for the first and 82% for the
second follow-up. In the study of Chambers et al. [38]
56% of the survivors participated in the follow-up, how-
ever no information was given regarding baseline
participation.
Assessment and categorization of PA
Apart from one article [34] which measured PA pro-
spectively at three points in time, all other studies [9,
30–33, 35–38] assessed PA only once. One study [33]
measured PA by using the Triaxial MOX activity moni-
tor (MMOXX1). The MMOXX1 is able to objectively
measure sedentary, standing and PA time. Apart from
Blanchard et al. [35] who only reported the adherence or
non-adherence to the American Cancer Society (ACS)
PA recommendations [39], all other studies [9, 30–32,
34–37] used validated PA instruments relying on
self-report. The questionnaire most frequently applied
was the Godin Leisure-Time Exercise Questionnaire
(GLTEQ) [40]. Several studies [9, 30, 31, 34, 35, 37] used
the PA guideline of the ACS [39] to differentiate be-
tween active and non-active survivors. The ACS recom-
mends at least 150 min of moderate intensity exercise
each week or 75 min of vigorous intensity activity each
week or an equivalent combination of both [39]. To fur-
ther quantify the intensity of the PA, metabolic equiva-
lent hours per week (MET–h/wk) [41] were used in five
articles [9, 32–34, 37]. In four of these articles light PA
(LPA) was defined as <3 MET–h/wk, whereas moderate
to vigorous PA (MVPA) was defined as an intensity of
≥3 MET–h/wk [9, 32, 34, 37]. One article [33] defined
PA as >1.5 MET–h/day and did not further differentiate
between LPA and MVPA.
QOL assessment
Quality of life was assessed only at one point in time in
most of the studies [9, 30–33, 35–37]. Only the two longi-
tudinal studies [34, 38] assessed QOL at different inter-
vals. Chambers et al. [38] assessed QOL five months
post-diagnosis and 5 years after diagnosis. Husson et al.
[34] assessed QOL in yearly intervals over a three year
period, starting with a baseline average time since diagno-
sis of 5.1 years. The QOL questionnaires most commonly
used were the EORTC QLQ-C30 [9, 32–34] and the
SF-36 [30, 31, 35, 37]. Information was collected by mail
in six studies [9, 30–32, 34–37], by telephone in five stud-
ies [30, 31, 35–38], and in person in one study [33]. One
study [32, 33] assessed only some of the EORTC
QLQ-C30 subscales and additionally used the Hospital
Anxiety and Depression Scale (HADS), the Checklist Indi-
vidual Strength (CIS), and the World Health Organization
Disability Assessment Schedule (WHODAS) question-
naire to assess QOL in CRC survivors.
Analysis, statistical methods, and clinical relevance
All studies compared CRC survivors who were active
with those who were less active or not active. Most
of the studies compared survivors who met the ACS
PA recommendations to those survivors who did not
[9, 30, 31, 34, 35, 37]. Two studies compared different
amounts of activity to a non-active reference group of
CRC survivors [36, 38]. Some studies compared survivors´
QOL according to higher and lower levels of LPA [32, 37]
and/or MVPA [32, 34, 36, 37]. One study additionally
compared lower with higher amounts of non-exercise
(e.g. gardening) and planned exercise (PA that is planned,
structured and repetitive e.g. jogging) [37].
All studies examined possible confounding factors
including age, sex, and comorbidities by some sort of
multivariable regression modeling or analysis of (co)vari-
ance. Six studies adjusted for body mass index (BMI)
and only three for smoking. Three studies performed
stratified analyses by age, sex, comorbidities, treatment,
and BMI for the association between PA and QOL.
Two studies [9, 34] reported clinical relevance for the
EORTC QLQ-C30. One study reported an overall clin-
ical relevance for the SF-36 of 5–10 score points mean
difference [37]. For some studies [30, 31, 35, 38] the
clinical relevance was not reported and could not be
derived from the available information. Moreover two
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studies used standard deviations to determine clinical
relevance [9, 33].
Study findings regarding the association between PA and
QOL
According to the included studies, 35–80% of the CRC
survivors met the ACS PA recommendations (Table 3).
Tables 4 and 5 and the Additional file 2: Table S2 and
Additional file 3: Table S3 show the study specific results
regarding the association between PA and QOL according
to type of analysis and type of QOL instrument. Since the
included studies used various QOL questionnaires, which
differ in included scales, not all studies contributed to the
results on every outcome and are thus not considered
when summarizing the respective findings.
Physically active vs. not active
Five of the six studies which compared active with
non-active CRC survivors, found positive associations
between PA and QOL (Table 4). Regarding specific sub-
scales, homogenous results were found for global QOL,
which was positively associated with PA in all of the five
studies which investigated global QOL. Differences in
global QOL between physically active versus non-active
survivors were clinically relevant in two [34, 37] of the
five studies. Three out of four studies reported a positive
association between PA and physical functioning, of
these two [34, 37] associations were of clinical relevance.
Two studies [30, 35] did not report any results on phys-
ical functioning. In contrast, results for role and social
functioning were more heterogeneous and less often sta-
tistically significant.
Different levels of PA and linear association of PA and
QOL
Table 5 shows the results from studies examining the as-
sociation between multiple levels of PA and QOL. Higher
QOL was associated with both, lower and higher levels of
PA intensity but the association between PA and QOL
depended on the specific QOL dimension. For instance,
survivors who had higher levels of LPA reported signifi-
cantly and clinically relevant higher physical functioning
than survivors who had lower LPA levels [32, 37], but no
association was found between global QOL, social
Table 4 Association of PA and QOL - Active vs. non-active
Statistical significance (p <0.05) and clinical relevance
+/−: significant positive/negative
association
ns: not statistically significant
.: not reported
a,b,cclinical relevance
Study C30 QL PF RF EF SF CF
Husson 2015 [34] Meeting vs. not meeting ACS PA guideline, Interindividuald +b +b +b +b +b +
Meeting vs. not meeting ACS PA guideline, Intraindividuale + + + ns ns ns
Mols 2015 [9] Meeting vs. not meeting ACS PA guideline +c +c +c +c +c +c
Study SF-36 PF RP BP SF MH RE VT GH GCS PCS MCS
Blanchard 2004 [35] Meeting vs. not meeting ACS PA guideline . . . . . . . . +c . .
Blanchard 2008 [30] Meeting vs. not meeting ACS PA guideline . . . . . . . . +c . .
Thraen-Borowski 2013 [37] Meeting vs. not meeting ACS PA guideline +a +a + +a ns ns +a +a . . .
Study FACT-C/ SWLS PWB SWB EWB FWB CCS SWLS
Chambers 2012 [38] Sedentary - Ref.
Insufficiently active (1–149 min/wk)
ns ns ns ns ns ns
Sufficiently active (≥150 min/wk) ns ns ns ns ns ns
Study PROMIS/ EQ-5D Physical HRQOL Mental HRQOL Overall HRQOL
Rodriguez 2015 [36] PA min/wk
No PA - Ref.
≤60, 61–149, 150–249, 250+
+c (≤60, 61–149,
150–249)
ns +c (≤60, 61–149,
150–249)
PA physical activity, QOL quality of life, C30 (European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire) QL global quality of life, PF
physical functioning, RF role functioning, EF emotional functioning, SF social functioning, CF cognitive functioning, ACS PA guideline American Cancer Society
physical activity recommendations of at least 150 min of MVPA per week, SF-36 (The Short Form Health Survey) PF physical functioning, RP role limitations due to
physical health problems, BP bodily pain, SF social functioning, MH general mental health, RE role limitations due to emotional problems, VT vitality, GH general
health perceptions, GCS global health composite score, PCS physical composite score, MCS mental composite score, FACT-C (Functional Assessment of Cancer
Therapy - Colorectal Cancer) PWB physical well-being, SWB social well-being, EWB emotional well-being, FWB functional well-being, CCS colorectal cancer scale,
SWLS (Satisfaction with Life Scale), Ref. Reference, min/wk minutes per week, PROMIS (Patient-Reported Outcomes Measurement Information System), EQ-5D
(EuroQol Five-Dimension Questionnaire), aclinical relevance reported by authors; bclinical relevance calculated by RE; cclinical relevance: no values, no cut-off for
calculation available; dinterindividual: patients average amount of PA/ average level PA of total group; eintraindividual: patients PA level at one time point/
patients average PA level
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Table 5 Association of PA and QOL - Different levels of PA and linear association
Statistical significance (p <0.05) and clinical relevance
Different levels of PA +/−: significant positive/negative
association
ns: not statistically significant
.: not reported
a,b,cclinical relevance
Study C30 QL PF RF EF SF CF
Van Roekel 2015 [32] >LPA (Q4 = ≥23.0 h/wk) vs.
<LPA (Q1 = ≤2.0 h/wk)
ns +b +b . ns .
>LPA (Q3 = 10.0-22.0 h/wk) vs.
<LPA (Q1 = ≤2.0 h/wk)
. . . . . .
>MVPA (Q4 =≥15.5 h/wk) vs.
<MVPA (Q1 =≤4.3 h/wk)
ns +b ns . ns .
>MVPA (Q3 = 8.7-15.0 h/wk) vs.
<MVPA (Q1 =≤4.3 h/wk)
ns . +b . +b .
Study SF-36 PF RP BP SF MH RE VT GH GCS PCS MCS
Thraen-Borowski
2013 [37]
>MVPA (Q4 =≥11.3 h/wk) vs.
<MVPA (Q1 = 0.0 h/wk)
. . . . . . . . . +b ns
>LPA (Q4 = ≥13.0 h/wk) vs.
<LPA (Q1 = ≤1.5 h/wk)d
. . . . . . . . . ns ns
>LPA (Q4 = ≥9.0 h/wk) vs.
<LPA (Q1 = 0.0 h/wk)e
. . . . . . . . . +b +b
>Planned exercisef (Q4 =≥9.5 h/wk) vs.
<Planned exercise (Q1 = 0.0 h/wk)
. . . . . . . . . +b ns
>Non-exerciseg (Q4 = ≥16.5 h/wk) vs.
<Non-exercise (Q1 =≤1.6 h/wk)
. . . . . . . . . + ns
Study WHODAS/ CIS/ HADS DIS FA DIST
Van Roekel 2015 [32] >LPA (Q4 = ≥23.0 h/wk) vs.
<LPA (Q1 = ≤2.0 h/wk)
–c ns ns
>LPA (Q3 = 10.0-22.0 h/wk) vs.
<LPA (Q1 = ≤2.0 h/wk)
ns –c ns
>MVPA (Q4 =≥15.5 h/wk) vs.
<MVPA (Q1 =≤4.3 h/wk)
ns ns ns
>MVPA (Q3 = 8.7-15.0 h/wk) vs.
<MVPA (Q1 =≤4.3 h/wk)
–c –c –c
Study PROMIS/ EQ-5D Physical HRQOL Mental HRQOL Overall HRQOL
Rodriguez 2015 [36] MVPA min/wk.
No MVPA - Ref.
≤60, 61–149, 150+
ns ns +c (61–149, 150
+)
ns (≤ 60)
Linear association PA and QOL (continuous results)
Study C30 QL PF RF EF SF CF
Hussonn 2015 [34] Continuous: Additional hour of MVPA/wk., Interindividualh + + + + + +
Continuous: Additional hour of MVPA/wk., Intraindividuali ns + ns ns ns +
Van Roekel 2016 [33] Single-variable model, PAj ns + ns . ns .
Partition model, PAk ns + ns . ns .
Substituting 1 h/day of sedentary time with PA ns +a ns . ns .
Substituting 1 h/day of standing time with PA ns ns ns . ns .
Study WHODAS/ CIS/ HADS DIS FA ANX DEP
Van Roekel 2016 [33] Single-variable model PAj –c ns ns ns
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functioning, and LPA [32], respectively. Positive associa-
tions between MVPA and physical functioning were found
in two [32, 37] of three [32, 36, 37] studies. Survivors who
reported higher MVPA levels reported significantly and
clinically relevant higher physical functioning compared
to survivors who had lower MVPA levels [32, 37].
When assessing PA as a continuous variable, signifi-
cant positive associations of MVPA with higher global
QOL, physical, emotional, social, and cognitive function-
ing were found [34]. Van Roekel et al. reported signifi-
cant positive associations between PA time (hour/day)
and physical functioning and disability, however, no as-
sociations were found for global QOL, role and social
functioning, fatigue, anxiety, and depression [33].
Further subgroup analyses and changes in the
association of PA and QOL over time
Only the study by van Roekel et al. provided results
stratified for age [33] and sex [32, 33] (Additional file 2:
Table S2). The association between PA and QOL did not
differ between younger and older survivors. However,
the association between LPA/PA and QOL seemed to be
stronger among women than among men. Women who
had higher LPA levels reported significantly and clinic-
ally relevant higher physical, role, and social functioning
and significantly less disability compared to women who
had lower LPA levels. The association of PA with global
QOL, fatigue, and distress was not statistically signifi-
cant. When substituting one hour of sedentary time with
PA, PA was clinically and significantly associated with
higher physical functioning and lower disability in
women. However, PA was not associated with global
QOL, role and social functioning, fatigue, anxiety, and
depression when substituting one hour of sedentary time
with PA. In both investigations no significant associa-
tions were found in men.
Van Roekel et al. [32, 33] reported heterogeneous re-
sults for the association between LPA/PA and QOL
stratified by number of comorbidities. Survivors with ≥2
comorbidities who reported higher levels of LPA re-
ported significantly and clinically relevant higher phys-
ical and role functioning and significantly less disability
than survivors with lower levels of LPA. No associations
were observed between higher levels of LPA and global
QOL, social functioning, fatigue, and distress. No associ-
ations were reported for LPA levels and any QOL scales
for survivors with <2 comorbidities [32]. In contrast,
when using sedentary time or standing time as a proxy
measures of (lack of ) PA, none of the QOL scales were
associated with PA in neither survivors with <2 nor sur-
vivors ≥2 comorbidities [33].
Heterogeneous results were also reported regarding
the association between PA and QOL with respect to
BMI. According to van Roekel et al. [33] non-obese sur-
vivors who were physically active reported higher global
QOL, lower depression and anxiety than less active
non-obese survivors. No association between PA and
QOL was found among obese survivors. In contrast, in
the study of Blanchard et al. [31] no associations be-
tween PA and QOL were found according to BMI.
Survivors without chemotherapy treatment who were
physically active scored significantly lower on the sen-
sory, motor, and autonomic scale of the European
Organization for Research and Treatment of Cancer
QLQ-CIPN20 Chemotherapy-induced peripheral neur-
opathy questionnaire (CIPN 20), compared to non-active
survivors [9]. The association between PA and QOL
among CRC survivors with chemotherapy treatment did
Table 5 Association of PA and QOL - Different levels of PA and linear association (Continued)
Statistical significance (p <0.05) and clinical relevance
Different levels of PA +/−: significant positive/negative
association
ns: not statistically significant
.: not reported
a,b,cclinical relevance
Study C30 QL PF RF EF SF CF
Partition model PAk ns ns ns ns
Substituting 1 h/day of sedentary time with PA ns ns ns ns
Substituting 1 h/day of standing time with PA ns ns ns ns
PA physical activity, QOL quality of life, C30 (European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire), QL global quality of life,
PF physical functioning, RF role functioning, EF emotional functioning, SF social functioning, CF cognitive functioning; > more; < less, LPA light physical activity
(<3 MET), Q Quartile, h/wk hours per week, MVPA moderate to vigorous physical activity (≥3 MET), SF-36 (The Short Form Health Survey) PF physical functioning,
RP role limitations due to physical health problems, BP bodily pain, SF social functioning, MH general mental health, RE role limitations due to emotional
problems, VT vitality, GH general health perceptions, GCS global health composite score, PCS physical composite score, MCS mental composite score, WHODAS
(World Health Organization Disability Assessment Schedule II) DIS disability, CIS (Checklist Individual Strength) FA fatigue, HADS (Hospital Anxiety and Depression
Scale), DIST distress, ANX anxiety, DEP depression, PROMIS (Patient-Reported Outcomes Measurement Information System), EQ-5D (EuroQol Five-Dimensions
Questionnaire), Ref. Reference, aclinical relevance reported by authors; bclinical relevance calculated by RE; cclinical relevance: no values, no cut-off for calculation
available; dparticipants reported LPA and MVPA; eparticipants reported only LPA; fintentional exercise e.g. jogging; gnon-intentional exercise e.g. gardening;
hinterindividual: patients average amount of PA/ average level PA of total group; iintraindividual: patients PA level at one time point/ patients average PA level;
jPA was entered separately in a single confounder-adjusted model, without adjustment for any of the other activities (sedentary, standing); kall activity categories
(sedentary, standing, PA) were entered simultaneously in a single confounder-adjusted model, to estimate independent associations of each activity category
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not substantially differ, only no significant associations
were found for PA and the autonomic scale. In both,
survivors with and without chemotherapy treatment, as-
sociations between PA and the motor scale were of clin-
ical relevance.
Only one study assessed PA and QOL at various points
in time among the same patients [34]. In CRC survivors
who were physically active over a three years period, role
and social functioning improved whereas role and social
functioning declined in non-active survivors. No associa-
tions were found between persistent PA and global QOL,
physical, emotional, and cognitive functioning [34].
Discussion
Key findings
The results from this systematic review demonstrate that
long-term CRC survivors who were more physically active
generally reported higher QOL than non-active survivors.
Moreover, different PA levels such as LPA and MVPA
seemed to be associated with QOL in long-term CRC sur-
vivors. The association between PA and QOL associations
seemed to be stronger among women than among men.
However, no general conclusion can be drawn, since only
few studies performed specific subgroup analyses.
To our knowledge, three review articles [10, 42, 43]
have been published on the associations between PA and
QOL in CRC survivors. However, the articles [10, 42, 43]
published so far were based on studies which mainly
included short-term CRC survivors and no systematic
review has specifically focused on long-term CRC sur-
vivors. The results which were found in this review art-
icle are quite homogenous. Eight of the ten included
articles found associations between PA and QOL,
whereas the results of the previous reviews are more in-
consistent. In line with our findings, Lynch et al. [10]
who included short-term and long-term survivors, also
reported associations between PA and QOL in observa-
tional studies. Otto et al. [43] reported that the associ-
ation between PA and QOL was stable over time but
only focused on short-term survivors. In contrast, the
review article and meta-analysis of Cramer et al. [42]
which included only short-term survivors did not find
an association between PA and HRQOL. The inconsist-
ent findings between our review and the previous
review articles might be explained in parts by the differ-
ent study population characteristics. The most obvious
difference is the varying time since diagnosis. Due to
the heterogeneous findings, it remains unclear whether
the overall effect of PA on QOL differs for short-term
and long-term CRC patients.
Limitations
Even though the majority of the studies, included in this
review had large sample sizes, were population based,
examined possible confounding factors like age, sex, and
comorbidities and used validated QOL and PA question-
naires, most of the included studies have some short-
comings which might limit their contributions to
existing evidence.
Nine of ten included articles assessed the association
between PA and QOL using a cross-sectional design. For
these studies we cannot assume causality, only an associ-
ation between PA and QOL at one point in time. More-
over, only few studies reported results stratified by
important covariates such as age, sex, or treatment. Al-
though the focus of this review article was on long-term
CRC survivors, only two studies [36, 37] were identified
that solely included long-term CRC survivors. All other
studies included short and long-term survivors with a
mean of 5 or more years since diagnosis. Thus, results of
the review are in parts not only based on long-term sur-
vivors. Since we did not include CRC survivors irre-
spective of time since diagnosis, but rather focused on
long-term survivors, testing for a moderating time since
treatment was not possible.
Given the older age of long-term CRC survivors and the
higher number of comorbid chronic conditions, it may be
reasonable to assume that the magnitude of the effect of
PA on QOL would be smaller, relative to short-term survi-
vors. However, in the majority of the included studies this
effect appears to remain statistically significant.
A further limitation of the current studies is that the ma-
jority used self-reported PA measures. Only one study [33]
used an activity monitor to assess PA. In this context, infor-
mation bias such as reporting bias might occur in studies
relying on self-reported PA levels or by only assessing leis-
ure time PA, but not work-related PA. Furthermore, there
were differences in the measurement tools used to assess
QOL which may also introduce some information bias.
Some studies [9, 32–34, 38] used cancer-specific QOL
questionnaires and other studies [30, 31, 35–37] used gen-
eral QOL instruments. Therefore the differences in the
QOL assessment might limit the comparability of the re-
sults. In addition, many QOL instruments specifically de-
signed for cancer patients under active treatment, such as
the EORTC QLQ-C30 and the FACT-G, with their supple-
mentary condition-specific or symptom-specific modules,
are not entirely appropriate or sufficient for assessing the
experience of disease free cancer survivors.
Furthermore, the sensitivity of QOL instruments and
scales to detect subtle differences in QOL may have had
an impact on the results. For example, two of the included
articles [31, 38] did not find any association between PA
and QOL. An explanation for the non-significant results
in the article of Chambers et al. [38] might be the use of
specific questionnaires (FACT-C, SWLS), which might
not be sufficiently sensitive. The other article [31] not
finding significant associations is based on the same study
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population as another included article [30] which found
associations between PA and QOL. However, the article of
Blanchard et al. which did not report significant results
[31], did not present the results for the general associa-
tions of PA with QOL again, but only reported the associ-
ation between PA and QOL stratified by BMI. Therefore
BMI might have been a confounding factor.
Due to the heterogeneity of the study methods and re-
sults, no meta-analysis could be performed.
As a result of early detection and treatment, more and
more CRC patients are becoming long-term survivors
[11]. Therefore, there is a need to maintain or improve
the QOL of these patients. Previous studies suggest that
counselling CRC survivors to engage in regular PA is
warranted to improve the prognosis of those patients.
The results of this review further support a positive as-
sociation between PA and QOL, however most included
studies have some limitations regarding the study design,
thus results should be interpreted with caution.
To overcome the aforementioned limitations and to
provide more evidence regarding the causality of a poten-
tial beneficial effect of PA on QOL, there is an urgent
need for more prospective studies assessing PA and QOL
at multiple points in time, preferably by using a random-
ized controlled trial design (e.g. [44]). Also future studies
should more often incorporate a prospective and validated
assessment of PA, for example by including objective ac-
tivity monitoring, in order to learn more about the
dose-response relationship of PA and QOL. More atten-
tion should be given to potential effect modification by
age, gender, type of treatment, stage, and other clinically
relevant patients´ characteristics. As health-related QOL
represents a multi-dimensional concept, studies should
use validated and reliable QOL instruments for which
clinically important differences have been established and
which cover both cancer-specific and general QOL mea-
sures regarding psychological as well as physical aspects.
In order to differentiate potential specific effects of PA on
QOL in CRC survivors from general effects of PA, add-
itional studies comparing CRC survivors with an
age-matched sample from the general population as con-
trols might be warranted.
Future studies including the aforementioned sugges-
tions may help to identify survivors who will benefit
most from PA intervention and to identify the point in
time and the level of PA that may be beneficial to CRC
survivors. Therefore, we may potentially be able to pro-
vide more specific and adequate recommendations re-
garding PA in CRC patients.
Conclusions
Despite the limitations of the existing evidence, the re-
sults of our systematic review indicate that overall, PA is
associated with better QOL in CRC survivors. Moreover,
different PA levels such as LPA and MVPA seemed to
be associated with QOL in long-term CRC survivors,
therefore it might be beneficial for long-term CRC survi-
vors to be physically active. Further prospective studies
and randomized controlled trials are needed to further
evaluate and confirm the causality of the association be-
tween PA and QOL specifically in long-term CRC survi-
vors, in order to provide more solid evidence for
individual PA recommendations.
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